POSA68 Cost Minimization Analysis of Fixed-Dose Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Open Triple Therapy for Moderate-to-Very Severe COPD in the United Kingdom
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.213
https://www.valueinhealthjournal.com/article/S1098-3015(21)02008-8/fulltext
Section Title :
Section Order :
10982
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02008-8&doi=10.1016/j.jval.2021.11.213